Biochimica et biophysica acta. Reviews on cancer最新文献_第5页

Molecular mechanisms of TAM-regulated tumorigenesis and progression in various types of radiotherapy and future prospects of radiation-immunotherapy combinations tam在不同类型放疗中调控肿瘤发生和进展的分子机制以及放射-免疫联合治疗的未来前景

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-29 DOI: 10.1016/j.bbcan.2025.189434

Luyu Liao , Yuzhao Jin , Wei Mao , Ji Zhu , Qianping Chen

{"title":"Molecular mechanisms of TAM-regulated tumorigenesis and progression in various types of radiotherapy and future prospects of radiation-immunotherapy combinations","authors":"Luyu Liao , Yuzhao Jin , Wei Mao , Ji Zhu , Qianping Chen","doi":"10.1016/j.bbcan.2025.189434","DOIUrl":"10.1016/j.bbcan.2025.189434","url":null,"abstract":"<div><div>Although conventional photon radiotherapy can eradicate tumors, the presence of radioresistance has limited treatment efficacy. Nowadays the multiple radiotherapies carried out around different physics beam types will provide more options for tumor treatment. Under the current trend of anti-tumor immunotherapy, tumor-associated macrophages (TAMs), as an important component of the tumor microenvironment, significantly influence tumor progression and prognosis of comprehensive tumor therapy through reciprocal regulation with radiotherapy. The aim of this review is to summarize the influence of radiotherapy with various beam types on the biological effects of TAMs, and to explore the physiological basis for the conjunction of radiotherapy and immunotherapy based on TAMs. Ultimately, these data will provide an evidence-based medical rationale and translational research basis for optimizing the combination of radiotherapy and immunotherapy as a treatment modality for tumors in the future.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189434"},"PeriodicalIF":9.7,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the power of innate lymphoid cell plasticity in the tumor microenvironment: A revolutionary pathway for cancer immunotherapy 解锁肿瘤微环境中先天淋巴细胞可塑性的力量：癌症免疫治疗的革命性途径

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-26 DOI: 10.1016/j.bbcan.2025.189430

Peng Yin , Pei Cao , Yu Liang , Chao Wang , Yu Tian

{"title":"Unlocking the power of innate lymphoid cell plasticity in the tumor microenvironment: A revolutionary pathway for cancer immunotherapy","authors":"Peng Yin , Pei Cao , Yu Liang , Chao Wang , Yu Tian","doi":"10.1016/j.bbcan.2025.189430","DOIUrl":"10.1016/j.bbcan.2025.189430","url":null,"abstract":"<div><div>Innate lymphoid cells (ILCs) are emerging as powerful players in the immune system, capable of dramatically influencing tumor immunity. Their extraordinary plasticity, which allows them to adapt to dynamic changes in the tumor microenvironment, positions them as a double-edged sword in cancer immunotherapy. While they can drive anti-tumor immune responses, they can also promote tumor progression under certain conditions. In this review, we delve into the multifaceted roles of ILCs—focusing on ILC1, ILC2, and ILC3—and explore how their functional plasticity can be harnessed to shift their activities from immune suppression to potent anti-tumor actions. We highlight groundbreaking therapeutic strategies aimed at modulating ILC plasticity, such as metabolic reprogramming, cytokine therapy, and CAR-ILC1 therapy, each designed to enhance the anti-tumor potential of these cells. Despite the immense promise, challenges remain, including immune suppression within the TME and the short-lived efficacy of cytokines. However, targeting ILC plasticity offers a transformative approach to overcome these hurdles, presenting an opportunity to personalize cancer treatment and create tailored immunotherapies that dynamically modulate the immune response. This review underscores the game-changing potential of ILC-based therapies and provides insights into the next generation of cancer immunotherapies that could revolutionize the fight against cancer.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189430"},"PeriodicalIF":9.7,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidimensional technological advances in cervical cancer screening: From standardized processes to precision medicine 宫颈癌筛查的多维技术进步：从标准化流程到精准医学

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-25 DOI: 10.1016/j.bbcan.2025.189432

Xiang Li , Jiaxin Zheng , Chang Liu , Bo Liu , Danbo Wang

{"title":"Multidimensional technological advances in cervical cancer screening: From standardized processes to precision medicine","authors":"Xiang Li , Jiaxin Zheng , Chang Liu , Bo Liu , Danbo Wang","doi":"10.1016/j.bbcan.2025.189432","DOIUrl":"10.1016/j.bbcan.2025.189432","url":null,"abstract":"<div><div>Cervical cancer is a common malignancy among women worldwide. To address this significant public health issue, the World Health Organization launched the “Eliminating Cervical Cancer” initiative. Effective screening of cervical cancer is crucial for reducing its morbidity and mortality. With continuous technological advancements, cervical cancer screening has evolved from traditional cytology and human papillomavirus (HPV) testing models to a new era of multidimensional, multilevel, and precise screening. This comprehensive review focuses on the core progress of screening technology in recent years, including the innovation of traditional screening methods, noninvasive optical imaging, molecular diagnosis from the perspective of precision medicine, and the deep integration and empowerment of artificial intelligence in the entire screening process. Cervical liquid-based cytology, combined with automated cell sorting technology and intelligent whole-slide image analysis, has achieved high-throughput identification of abnormal cells. The accuracy and specificity of HPV and multiomic biomarker detection technologies have significantly improved, providing a new basis for the accurate triage of patients with high-risk infections. Noninvasive cervical imaging technology already offers early identification of cervical precancerous lesions at the molecular level, combining ease of use with good patient acceptance. Notably, artificial intelligence technology is being integrated into multiple screening processes, leveraging horizontal integration and cross-platform capabilities in image recognition, risk assessment, auxiliary diagnosis, and automated testing processes, becoming a key driver of innovation in screening systems.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189432"},"PeriodicalIF":9.7,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144908469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trogocytosis at crossroads: Navigating the duality in tumor-immune cell interactions Trogocytosis在十字路口：导航肿瘤免疫细胞相互作用的双重性。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-25 DOI: 10.1016/j.bbcan.2025.189431

Xin Yang , Xiaolu Huang , Zhuonan Chen , Wei Zhang , Ousheng Liu , Jianjun Wu , Fei Yan

{"title":"Trogocytosis at crossroads: Navigating the duality in tumor-immune cell interactions","authors":"Xin Yang , Xiaolu Huang , Zhuonan Chen , Wei Zhang , Ousheng Liu , Jianjun Wu , Fei Yan","doi":"10.1016/j.bbcan.2025.189431","DOIUrl":"10.1016/j.bbcan.2025.189431","url":null,"abstract":"<div><div>Trogocytosis, derived from the Greek “trogo-,” meaning “nibble,” is a cellular process in which one cell extracts membrane fragments and surface molecules from another, modulating the functions of both donor and recipient cells. In tumor immunology, trogocytosis between immune cells and tumor cells exhibits paradoxical effects. Conflicting reports suggest it can enhance antitumor effects through processes like trogoptosis, antigen presentation, and beneficial antigen shaving, while facilitating protumor effects by antigen masking, immune cell exhaustion, immune cell fratricide, and detrimental antigen shaving. In this review, we discuss recent insights in trogocytosis between immune cells (T cells, natural killer cells, neutrophils, monocytes/macrophages, chimeric antigen receptor cells, and antigen-presenting cells) and tumor cells, summarize the distinct interaction patterns and characteristics, and highlight its dual role in enhancing anti-tumor immunity and facilitating tumor immune evasion. Additionally, we explore the strategies to exploit trogocytosis in immunotherapy, aiming to deepen insights into immune-tumor interactions and to improve therapeutic outcomes.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189431"},"PeriodicalIF":9.7,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dysregulated YY1-EZH2-RKIP axis in cancer cells and immune evasion 癌细胞中YY1-EZH2-RKIP轴失调与免疫逃避

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-21 DOI: 10.1016/j.bbcan.2025.189424

Talia Festekdjian, Benjamin Bonavida

{"title":"The dysregulated YY1-EZH2-RKIP axis in cancer cells and immune evasion","authors":"Talia Festekdjian, Benjamin Bonavida","doi":"10.1016/j.bbcan.2025.189424","DOIUrl":"10.1016/j.bbcan.2025.189424","url":null,"abstract":"<div><div>We have recently witnessed several milestones in the treatment of a subset of cancer patients with immunotherapy and resulting in significant clinical responses. However, there is a subset that is unresponsive due to resistant factors in the cancer cells that are responsible for immune evasion. The characterization of such factors might lead to novel targeted therapies to restore the anti-tumor immunotherapies. We describe three dysregulated gene products, namely, Yin Yang1 (YY1), EZH2, and RKIP (PEBP1), that play pivotal roles in immune evasion. We report on the various molecular regulatory roles and signaling pathways that lead to the overexpression of YY1 and EZH2 and under expression of RKIP in cancer cells and established cross-talk signaling pathways amongst these three gene products. Such cross-talks established the dysregulated YY1-EZH2-RKIP axis and its pivotal role in the regulation of immune evasion. Thus, this axis is a potentially new therapeutic target to inhibit immune evasion by targeting the inhibition of YY1 or EZH2 or the induction of RKIP. Various agents are discussed to target each of these gene products, alone or in combination, to be investigated preclinically. However, the specific targeting to the tumor cells and sparing normal tissues is challenging, though new approaches are feasible.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189424"},"PeriodicalIF":9.7,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144893904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted drug delivery systems in Lymphoma treatment: Advances and clinical perspectives 淋巴瘤治疗中的靶向药物输送系统：进展和临床前景

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-21 DOI: 10.1016/j.bbcan.2025.189429

Qianqian Guo , Yingshu Luo , Xin Wang , Shunfeng Hu

{"title":"Targeted drug delivery systems in Lymphoma treatment: Advances and clinical perspectives","authors":"Qianqian Guo , Yingshu Luo , Xin Wang , Shunfeng Hu","doi":"10.1016/j.bbcan.2025.189429","DOIUrl":"10.1016/j.bbcan.2025.189429","url":null,"abstract":"<div><div>Lymphomas are a heterogeneous group of hematologic tumors that pose a significant challenge in precise treatment. With the development of novel intervention strategies in lymphoma, such as targeted drugs and cell therapy, the prognosis and outcome of lymphoma patients have been greatly improved. However, there are also about 30 % of patients that display recurrence and eventually die, mainly due to the low effectiveness and targeting of current treatments. The advancements in novel drug delivery systems have revolutionized drug efficacy and tumor targeting in lymphoma treatment. Over the past few decades, various drug delivery systems, including nanocarriers, proteins, aptamers, and exosomes, have shown promising prospects in targeted therapy for lymphoma. These targeted delivery systems could carry anti-lymphoma drugs through physical embedding or chemical conjugation, which mitigate side effects and enhance therapeutic efficacy by ameliorating toxicity, prolonging systemic circulation time, and facilitating crossing of the blood-brain barrier. This review aims to summarize different drug delivery systems employed in lymphoma treatment and highlight their current applications and potential future implications, which might pave the way for the development of targeted therapy in lymphoma.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189429"},"PeriodicalIF":9.7,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144912384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fatty acid addiction in cancer: A high-fat diet directly promotes tumor growth through fatty acid oxidation 癌症中的脂肪酸成瘾：高脂肪饮食通过脂肪酸氧化直接促进肿瘤生长

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-20 DOI: 10.1016/j.bbcan.2025.189428

Soo-Youl Kim

引用次数: 0

Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance mechanisms in prostate cancer 整合多组学蛋白质组学方法解读前列腺癌肿瘤微环境和治疗耐药机制

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-20 DOI: 10.1016/j.bbcan.2025.189426

Yutao Wang , Fan Wang , Qi Pan , Jianfeng Wang

{"title":"Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance mechanisms in prostate cancer","authors":"Yutao Wang , Fan Wang , Qi Pan , Jianfeng Wang","doi":"10.1016/j.bbcan.2025.189426","DOIUrl":"10.1016/j.bbcan.2025.189426","url":null,"abstract":"<div><div>Prostate cancer (PCa) is one of the main causes of cancer-related mortality. The tumor microenvironment (TME) and the development of drug resistance pose significant challenges to effective cancer therapy. This review explores the integration of multi-omics proteomic approaches to decipher the complex interactions within the TME and the mechanisms driving resistance in PCa. We discuss how proteomics and genomics, transcriptomics, and metabolomics enhance our understanding of the molecular drivers of cancer progression, immune evasion, and treatment failure. Emphasis is placed on recent advances in proteomic profiling of the TME, including extracellular matrix components and immune regulators, and how single-cell proteomics provides insights into tumor heterogeneity. We also highlight the multi-omics role in identifying post-translational modifications and kinase pathways contributing to therapeutic resistance, and its implications for biomarker discovery and personalized medicine. The review concludes by addressing the clinical potential of multi-omics approaches and their future role in improving outcomes for prostate cancer patients.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189426"},"PeriodicalIF":9.7,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144889046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances of mRNA vaccines in genitourinary cancers 泌尿生殖系统肿瘤mRNA疫苗研究进展

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-20 DOI: 10.1016/j.bbcan.2025.189427

You-Min Shen , Fang-Ning Wan , Hua Xu , Liu Yu , Sheng-Lin Huang , Ding-Wei Ye , Bo Dai

{"title":"Advances of mRNA vaccines in genitourinary cancers","authors":"You-Min Shen , Fang-Ning Wan , Hua Xu , Liu Yu , Sheng-Lin Huang , Ding-Wei Ye , Bo Dai","doi":"10.1016/j.bbcan.2025.189427","DOIUrl":"10.1016/j.bbcan.2025.189427","url":null,"abstract":"<div><div>The rapid advancements and declining costs of mRNA technology have led to a significant rise in the use of mRNA-based interventions recently. Unlike traditional drug design schemes, mRNA vaccines rely on next-generation sequencing (NGS) results and were designed individually. mRNA vaccine technology enables the encoding of tumor-specific antigens (neoantigens) to activate immune responses and the delivery of cytokines to modulate the tumor microenvironment. It can also introduce tumor suppressor genes to inhibit tumor progression and supply chimeric antigen receptors for T cell-based therapies. mRNA-based approaches have shown great promise in preclinical studies, with several progressing to clinical trials. The established safety and effectiveness of authorized mRNA vaccines, combined with a growing interest in mRNA therapeutics, indicate that mRNA technology is set to play a vital role in advancing cancer treatments. In this review, we summarize the development of mRNA vaccines in genitourinary cancers, encompassing the attributes of diverse synthetic mRNA types, efficient mRNA delivery systems, a spectrum of preclinical and clinical investigations, and the current hurdles and upcoming opportunities within this area.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189427"},"PeriodicalIF":9.7,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144912385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elucidating cellular origins and TME dynamic evolution in NSCLC through multi-omics technologies 通过多组学技术阐明非小细胞肺癌的细胞起源和TME动态进化

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-08-19 DOI: 10.1016/j.bbcan.2025.189425

Ning Ning Chao, Li Zhang

{"title":"Elucidating cellular origins and TME dynamic evolution in NSCLC through multi-omics technologies","authors":"Ning Ning Chao, Li Zhang","doi":"10.1016/j.bbcan.2025.189425","DOIUrl":"10.1016/j.bbcan.2025.189425","url":null,"abstract":"<div><div>Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality. Despite progress in targeted therapies and immunotherapy, resistance driven by tumor heterogeneity and dynamic tumor microenvironment (TME) remodeling persists. Multi-omics (single-cell/spatial transcriptomics) reveals lung adenocarcinoma (LUAD) origins in alveolar type 2 (AT2) cells and lineage plasticity via SOX2/WNT/YAP pathways driving aggressive subtypes. The TME, a dynamic ecosystem of immune cells and fibroblasts, evolves through immune-editing phases and cancer-associated fibroblasts (CAF)/tumor-associated macrophage (TAM) crosstalk to foster immunosuppression. Multi-omics identifies key immune subsets (CXCL13<sup>+</sup>CD8<sup>+</sup>T cells, M1/M2 macrophages) and antigen-presenting cancer-associated fibroblasts (apCAFs) as therapeutic targets. Emerging strategies targeting lineage plasticity, TME reprogramming, and microbiome modulation may overcome immune checkpoint blockade (ICB)/tyrosine kinase inhibitor (TKI) resistance. Challenges in spatiotemporal heterogeneity resolution call for artificial intelligence (AI)-driven TME modeling to guide precision interventions. This review highlights multi-omics in bridging NSCLC evolution with clinical translation for personalized therapies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189425"},"PeriodicalIF":9.7,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0